Gennova''S MRNA-Based COVID-19 Vaccine Gets Approval For Phase 2/3 Clinical Trials

[email protected]17 Sep, 2021News

New Delhi, Aug 24 (PTI) India''s first mRNA-based COVID-19 vaccine candidate HGCO19 by Gennova Biopharmaceuticals Ltd has been granted approval for Phase 2/3 clinical trails, the Department of Biotechnology (DBT) said on Tuesday. The Pune-based biotechnology company had submitted the interim clinical data of the vaccine''s Phase 1 study to the Central Drugs Standard Control Organisation (CDSCO), it said.